Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivacaftor for pancreatic exocrine function in cystic fibrosis with G551D mutation
ACTRN12614000356662Phase 4Recruiting
- Sponsor
- Sydney Children's Hospitals Network
- Start
- Mar 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of ivacaftor in cystic fibrosis (CF), sponsored by Sydney Children's Hospitals Network. Primary endpoint: Exocrine pancreatic function. Started Mar 2014; status: recruiting.
02
Drugs
ivacaftor
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on ACTRN12614000356662.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12614000356662.